BIX 2026 Counts Down to Opening with Post-GLP-1 Session on the Next Obesity Treatment Market
BIX 2026 Highlights Post-GLP-1 Obesity Market
Seoul, Korea, South, October 23, 2026 --(PR.com)-- RX Korea, organizer of BIOPLUS-INTERPHEX KOREA (BIX) 2026, has unveiled the full conference schedule for Korea's leading biotechnology and pharmaceutical convention, highlighting key discussions on next-generation therapeutics, artificial intelligence, investment trends, and the evolving obesity treatment market.
Set to take place from October 28 to 30, 2026, at COEX in Seoul, BIX 2026 reflects RX's commitment to creating platforms that connect industry leaders, foster innovation, and support business growth across the global life sciences sector. The event is expected to bring together more than 300 companies and over 90 speakers from Korea and around the world.
As one of RX's flagship events in the biotechnology and pharmaceutical space, BIX 2026 will provide a forum for industry stakeholders to examine emerging technologies, market developments, regulatory considerations, and business strategies shaping the future of healthcare and biopharmaceutical innovation.
This year's conference agenda spans a wide range of topics, including AI-driven drug discovery, radiopharmaceuticals (RPT), NewCo business models, investment and M&A activity, global market expansion, and new opportunities in preventive nutrition, connected care, space biotechnology, animal health, and beauty.
Among the featured sessions is “Post-GLP-1: Who Will Lead the Next Expansion of the Obesity Market?,” which will explore opportunities and challenges emerging from the rapid growth of the global obesity treatment market following the commercial success of GLP-1 therapies.
As competition intensifies among next-generation obesity treatment developers, factors such as patient accessibility, manufacturing scalability, pricing strategies, and international partnerships are becoming increasingly important in determining long-term market leadership. Through this dedicated session, RX aims to facilitate industry dialogue on the future direction of obesity and metabolic disease innovation.
The session will feature insights from leading investors, pharmaceutical executives, and biotechnology innovators, including:
Billy Cho, PE and Head of JVC, CBC Group
Huizhong Xiong, Vice President of Innovent Biologics
Inyoung Choi, PhD, Senior Executive Vice President and Head of R&D Division, Hanmi Pharmaceutical
Seulki Lee, CEO, D&D Pharmatech
Cho will discuss investment considerations shaping the obesity therapeutics sector, including efficacy, pricing, patient access, supply capabilities, and recent dealmaking trends. Xiong will share perspectives on global commercialization strategies and international partnerships for obesity and metabolic disease therapies. Choi will provide insights into differentiation, partnering, and market access strategies from the perspective of a Korean pharmaceutical company, while Lee will examine emerging treatment approaches and novel mechanisms designed to address unmet needs beyond current GLP-1 therapies.
“The bioindustry's business strategies are evolving rapidly as next-generation therapeutics, advances in AI, shifting investment and M&A dynamics, and intensifying global competition converge,” said Seung-kyou Lee, Vice President of Korea Biotechnology Industry Organization (KoreaBIO). “We hope BIX 2026 will be a platform where key players across the industry come together to share real-world market insights and strategies and discover new partners and business opportunities.”
In addition to its conference program, BIX 2026 will feature approximately 600 exhibition booths, enabling biotechnology, pharmaceutical, and healthcare organizations from around the world to explore partnerships, technologies, and business opportunities. Through RX's business matching platform, exhibitors and registered attendees can identify prospective partners and arrange meetings before the event.
By bringing together innovators, investors, researchers, manufacturers, and healthcare leaders, RX continues to support industry collaboration and the advancement of biotechnology through BIX 2026.
For the full conference schedule, speaker lineup, exhibitor information, and registration details, visit the official BIX 2026 website.
Set to take place from October 28 to 30, 2026, at COEX in Seoul, BIX 2026 reflects RX's commitment to creating platforms that connect industry leaders, foster innovation, and support business growth across the global life sciences sector. The event is expected to bring together more than 300 companies and over 90 speakers from Korea and around the world.
As one of RX's flagship events in the biotechnology and pharmaceutical space, BIX 2026 will provide a forum for industry stakeholders to examine emerging technologies, market developments, regulatory considerations, and business strategies shaping the future of healthcare and biopharmaceutical innovation.
This year's conference agenda spans a wide range of topics, including AI-driven drug discovery, radiopharmaceuticals (RPT), NewCo business models, investment and M&A activity, global market expansion, and new opportunities in preventive nutrition, connected care, space biotechnology, animal health, and beauty.
Among the featured sessions is “Post-GLP-1: Who Will Lead the Next Expansion of the Obesity Market?,” which will explore opportunities and challenges emerging from the rapid growth of the global obesity treatment market following the commercial success of GLP-1 therapies.
As competition intensifies among next-generation obesity treatment developers, factors such as patient accessibility, manufacturing scalability, pricing strategies, and international partnerships are becoming increasingly important in determining long-term market leadership. Through this dedicated session, RX aims to facilitate industry dialogue on the future direction of obesity and metabolic disease innovation.
The session will feature insights from leading investors, pharmaceutical executives, and biotechnology innovators, including:
Billy Cho, PE and Head of JVC, CBC Group
Huizhong Xiong, Vice President of Innovent Biologics
Inyoung Choi, PhD, Senior Executive Vice President and Head of R&D Division, Hanmi Pharmaceutical
Seulki Lee, CEO, D&D Pharmatech
Cho will discuss investment considerations shaping the obesity therapeutics sector, including efficacy, pricing, patient access, supply capabilities, and recent dealmaking trends. Xiong will share perspectives on global commercialization strategies and international partnerships for obesity and metabolic disease therapies. Choi will provide insights into differentiation, partnering, and market access strategies from the perspective of a Korean pharmaceutical company, while Lee will examine emerging treatment approaches and novel mechanisms designed to address unmet needs beyond current GLP-1 therapies.
“The bioindustry's business strategies are evolving rapidly as next-generation therapeutics, advances in AI, shifting investment and M&A dynamics, and intensifying global competition converge,” said Seung-kyou Lee, Vice President of Korea Biotechnology Industry Organization (KoreaBIO). “We hope BIX 2026 will be a platform where key players across the industry come together to share real-world market insights and strategies and discover new partners and business opportunities.”
In addition to its conference program, BIX 2026 will feature approximately 600 exhibition booths, enabling biotechnology, pharmaceutical, and healthcare organizations from around the world to explore partnerships, technologies, and business opportunities. Through RX's business matching platform, exhibitors and registered attendees can identify prospective partners and arrange meetings before the event.
By bringing together innovators, investors, researchers, manufacturers, and healthcare leaders, RX continues to support industry collaboration and the advancement of biotechnology through BIX 2026.
For the full conference schedule, speaker lineup, exhibitor information, and registration details, visit the official BIX 2026 website.
Contact
RX Korea
Jo Jiyeon
+81-3-6739-4120
Jo Jiyeon
+81-3-6739-4120
Contact
Categories